Literature DB >> 10990084

A specific structural alteration in the heparan sulphate of human glomerular basement membrane in diabetes.

A S Edge1, R G Spiro.   

Abstract

AIMS/HYPOTHESIS: Heparan sulphate proteoglycan is an important component of the glomerular anionic filtration barrier and its reduced amount in diabetes contributes to glomerular dysfunction. The objective of this study was to determine if there is also an alteration in the sulphation pattern of the diabetic heparan sulphate chains.
METHODS: The heparan sulphate in the glomerular basement membrane/mesangial matrix from human diabetic and nondiabetic kidneys obtained at autopsy was fragmented by a hydrazine/nitrous acid procedure and after radiolabelling with NaB[3H]4, the disaccharide products were chromatographically resolved and quantified.
RESULTS: Six sulphated disaccharides were identified in both the diabetic and nondiabetic samples and the molar distribution of these was similar, with the notable exception of the iduronic acid-2-O-sulphatectl--> 4glucosamine-3-O-sulphate species which occurred in the diabetic glomeruli in less than half the amount as in the nondiabetic samples (9.0% compared to 18.7% of total sulphated disaccharides, p < 0.005). CONCLUSION/
INTERPRETATION: 3-O-sulphated glucosamine is a rare constituent of heparan sulphate occurring usually in a glucuronic acidbeta1--> 4glucosamine-3-O-sulphate(+/- 6-O-sulphate) sequence within the antithrombin-binding domain. In the glomerular basement membrane where the 3-O-sulphated glucosamine is present in substantial amounts, however, it occurs exclusively in an iduronic acid-containing sequence. It is likely that the recently discovered 3-O-sulphotransferase variant which specifically acts on the iduronic acidalpha1--> 4glucosamine sequence is decreased in human diabetes and moreover that this unusual disaccharide could be a component of a specific heparan sulphate domain which interacts with bioactive proteins.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10990084     DOI: 10.1007/s001250051489

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  5 in total

1.  Inhibition of heparanase protects against pancreatic beta cell death in streptozotocin-induced diabetic mice via reducing intra-islet inflammatory cell infiltration.

Authors:  Wen-Yu Song; Xiao-Han Jiang; Ying Ding; Yan Wang; Ming-Xuan Zhou; Yun Xia; Chen-Yu Zhang; Chong-Chong Yin; Chen Qiu; Kai Li; Peng Sun; Xiao Han
Journal:  Br J Pharmacol       Date:  2020-08-19       Impact factor: 8.739

2.  Diabetes induces stromal remodelling and increase in chondroitin sulphate proteoglycans of the rat ventral prostate.

Authors:  Daniele Lisboa Ribeiro; Sebastião Roberto Taboga; Rejane Maira Góes
Journal:  Int J Exp Pathol       Date:  2009-08       Impact factor: 1.925

3.  Characterization of heparan sulphate 3-O-sulphotransferase isoform 6 and its role in assisting the entry of herpes simplex virus type 1.

Authors:  Ding Xu; Vaibhav Tiwari; Guoqing Xia; Christian Clement; Deepak Shukla; Jian Liu
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

4.  Reactive oxygen species modulate the barrier function of the human glomerular endothelial glycocalyx.

Authors:  Anurag Singh; Raina D Ramnath; Rebecca R Foster; Emma C Wylie; Vincent Fridén; Ishita Dasgupta; Borje Haraldsson; Gavin I Welsh; Peter W Mathieson; Simon C Satchell
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

5.  The protective role of fucosylated chondroitin sulfate, a distinct glycosaminoglycan, in a murine model of streptozotocin-induced diabetic nephropathy.

Authors:  Conrado L R Gomes; Cristina L Leão; Carolina Venturotti; André L Barreira; Gabriela Guimarães; Roberto J C Fonseca; Rodrigo S Fortunato; Paulo A S Mourão; Alvimar G Delgado; Christina M Takiya; Maurilo Leite
Journal:  PLoS One       Date:  2014-09-05       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.